Development of Pulmonary Hypertension in an Infant Treated With Diazoxide for Hyperinsulinism, a Case Report and Literature Review
American Journal of Pediatrics
Volume 1, Issue 1, July 2015, Pages: 1-3
Received: Jun. 27, 2015; Accepted: Jul. 20, 2015; Published: Jul. 23, 2015
Views 4538      Downloads 97
Authors
Albahri Ziad, Department of Pediatrics, Faculty Hospital, Charles University, Hradec Kralove, Czech Republic
Lukeš Antonín, Department of Pediatrics, Faculty Hospital, Charles University, Hradec Kralove, Czech Republic
Mynářová Kateřina, Department of Pediatrics, Faculty Hospital, Charles University, Hradec Kralove, Czech Republic
Krylová Kateřina, Department of Pediatrics, Faculty Hospital, Charles University, Hradec Kralove, Czech Republic
Al Mawiri Abdul, Internal medicine- Faculty Hospital, Charles University, Hradec Kralove, Czech Republic
Hussain Khaled, Department of Paediatric Endocrinology, Institute of Child Health, University College, London, United Kingdom
Neumann David, Department of Pediatrics, Faculty Hospital, Charles University, Hradec Kralove, Czech Republic
Article Tools
Follow on us
Abstract
Congenital hyperinsulinism (CHI) is heterogeneous disorder in the neonatal period characterized by inappropriate insulin secretion in the presence of hypoglycemia. Known etiologies include inactivating mutations of the KATP channel. Its management can be extremely complicated, and may involve medical therapy and surgery. We describe a full term baby male at one month-old without dysmorphic features or congenital anomalies, the baby was presented with asymptomatic hypoglycemia by routine screening at the age of 1.5 hour of life, he was treated with diazoxide for prolonged neonatal hyperinsulinism. Tolerance of diazoxide is usually excellent, but several adverse effects of this drug have been described. During diazoxide therapy he presented with tachycardia and low oxygen saturation, the baby became dyspnoeic with fluid retention and facial edema. Echocardiography showed moderate pulmonary hypertension. Diazoxide was withdrawn, his clinical status and pulmonary hypertension dramatically improved and returned to baseline.
Keywords
Hyperinsulism, Diazoxide, Pulmonary Hypertension
To cite this article
Albahri Ziad, Lukeš Antonín, Mynářová Kateřina, Krylová Kateřina, Al Mawiri Abdul, Hussain Khaled, Neumann David, Development of Pulmonary Hypertension in an Infant Treated With Diazoxide for Hyperinsulinism, a Case Report and Literature Review, American Journal of Pediatrics. Vol. 1, No. 1, 2015, pp. 1-3. doi: 10.11648/j.ajp.20150101.11
References
[1]
Yorifuji T. Congenital hyperinsulinism: current status and future perspectives. Ann Pediatr Endocrinol Metab. 2014; 19(2):57-68.
[2]
Arnoux JB, Verkarre V, Saint-Martin C, Montravers F, Brassier A, Valayannopoulos V, Brunelle F, Fournet JC, Robert JJ, Aigrain Y, Bellanné-Chantelot C, de Lonlay P. Congenital hyperinsulinism: current trends in diagnosis and therapy. Orphanet J Rare Dis. 2011;6:63.
[3]
Gopal-Kothandapani JS, Hussain K. Congenital hyperinsulinism: Role of fluorine-18L-3, 4 hydroxyphenylalanine positron emission tomography scanning. World J Radiol. 2014 28;6(6):252-260.
[4]
Lovvorn HN 3rd, Nance ML, Ferry RJ Jr, Stolte L, Baker L, O'Neill JA Jr, Schnaufer L, Stanley CA, Adzick NS. Congenital hyperinsulinism and the surgeon: lessons learned over 35 years. J Pediatr Surg. 1999;34(5):786-92; discussion 792-793.
[5]
Parker JJ, Allen DB. Hypertrophic cardiomyopathy after prolonged diazoxide therapy for hyperinsulinemic hypoglycemia. J Pediatr. 1991;118(6):906-909.
[6]
Yildizdas D, Erdem S, Küçükosmanoglu O, Yilmaz M, Yüksel B. Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy. Adv Ther. 2008;25(5):515-519.
[7]
Price LC, McAuley DF, Marino PS, Finney SJ, Griffiths MJ, Wort SJ. Pathophysiology of pulmonary hypertension in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2012;302(9):L803-815.
[8]
Silvani P, Camporesi A Drug-induced pulmonary hypertension in newborns: a review. Curr Vasc Pharmacol. 2007;5(2):129-133. Review.
[9]
Demirel F, Unal S, Ç etin II, Esen I, Arasli A. Pulmonary hypertension and reopening of the ductus arteriosus in an infant treated with diazoxide. J Pediatr Endocrinol Metab. 2011;24(7-8):603-605.
[10]
Yildizdas D, Erdem S, Küçükosmanoglu O, Yilmaz M, Yüksel B. Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy. Adv Ther. 2008;25(5):515-519.
[11]
Nebesio TD, Hoover WC, Caldwell RL, Nitu ME, Eugster EA. Development of pulmonary hypertension in an infant treated with diazoxide. J Pediatr Endocrinol Metab. 2007;20(8):939-944.
[12]
Senguttuvan R, Saleh M, Wheeler M, Patel Ch, Chin C and Patel P. Diazoxide induced pulmonary hypertension in an infant. Endocrine Society's 96th Annual Meeting and Expo, June 21–24, 2014 – Chicago.
[13]
Silvani P, Camporesi A, Mandelli A, Wolfler A, Salvo I. A case of severe diazoxide toxicity. Paediatr Anaesth. 2004;14(7):607-609.
ADDRESS
Science Publishing Group
548 FASHION AVENUE
NEW YORK, NY 10018
U.S.A.
Tel: (001)347-983-5186